Belite Bio advances tinlarebant submissions in three more markets including the UK
Belite Bio, a clinical stage drug development company, has recently announced that it has submitted applications for marketing approval of tinlarebant in several countries.
In a nutshell:
Belite Bio has submitted applications for marketing approval of tinlarebant, an investigational once-daily oral treatment designed to slow vision loss in people with Stargardt disease type 1 (STGD1), in the US, Japan, Singapore, Switzerland and the UK. Following encouraging Phase 3 DRAGON trial results, the latest submissions in Singapore, Switzerland and the UK were made through the Access Consortium, which enables regulators to collaborate during the review process. While this marks an important step towards potential treatment availability, approval has not yet been guaranteed, and the timeline for patient access, including potential NHS availability, remains uncertain.
What is tinlarebant?
Tinlarebant is an orally administered, once-a-day tablet which aims to slow vision loss by addressing some of the damaging toxin accumulation that occurs in the retina as a result of Stargardt disease. To read more about how tinlarebant works, please visit our article using the following link: Belite Bio – Phase 2/3 Trial for Adolescents with Stargardt disease – Retina UK.
The investigational treatment showed encouraging results in its phase 3 trial known as DRAGON. Tinlarebant was shown to reduce the growth rate of atrophic lesions by about a third compared to those who received the placebo. Belite Bio also reported that the safety profile remained consistent with previous studies and the drug was well tolerated by participants. To learn more about the results of this trial, please visit our article using the following link: Belite Bio announces promising phase 3 results for Stargardt disease – Retina UK
Marketing Authorisation Applications:
Belite Bio has submitted Marketing Authorisation Applications, known as MAAs, to regulatory authorities in Singapore, Switzerland and the UK for tinlarebant.
A regulatory body is an organisation that makes sure that medical treatments are safe, effective and of high quality before they can be offered to patients more widely. Examples include the FDA in the United States and the MHRA in the United Kingdom. Each of these organisations exist because healthcare systems, laws and public safety standards vary from country to country.
Getting approval isn’t instant. Each regulatory body has its own questions, forms and requirements when reviewing research data. That’s why it can take a while for a new treatment to reach regulatory agreement across multiple countries.
However, excitingly, these multi-market applications have been submitted via the Access Consortium framework in agreement with the regulatory bodies that govern Singapore, Switzerland and the UK. The Access Consortium is designed to maximise regulatory collaboration to support a more timely review process across multiple countries at the same time. The three participating regulators can collaborate and share assessment work, helping to reduce any unnecessary duplication and potentially streamlining the review process through this coordinated pathway. However, this does not guarantee that an approval will be reached or that a faster decision will occur. Each regulator still retains responsibility for its own country’s authorisation, meaning that the consortium does not automatically approve a treatment across all member countries.
“These submissions are an important step toward making tinlarebant available globally to people living with STGD1. Filing through the Access Consortium allows us to pursue authorization across three additional countries in parallel. We are confident in our robust data showing tinlarebant’s ability to slow the growth rate of retinal lesions compared to placebo, and we look forward to working with each agency through their reviews. If approved, tinlarebant would become the first therapy approved for STGD1 in Singapore, the United Kingdom, and Switzerland.” – Dr. Tom Lin, Chairman and Chief Executive Officer of Belite Bio
What does this mean for the Retina UK community?
This means that Belite Bio have now submitted applications for approval to the US, Japan, Singapore, Switzerland and the UK and hold multiple regulatory designations such as priority review and accelerated approval, all of which aim to speed up the regulatory review process of tinlarebant.
Whilst these submissions are an important regulatory milestone, tinlarebant must still undergo assessment by each regulatory body and the potential approval timeline and subsequent patient access remain uncertain. Reaching agreement for NHS availability is a further, separate process. As a result, there may be a significant wait before a treatment becomes widely available.
This is an exciting update for our Stargardt Community. However, please note that we hold no further information on if and when this treatment may become available. For any questions regarding tinlarebant and Belite Bio, please contact them directly via their online form found here: Contact Us | Belite Bio.